Oral Administration of Latilactobacillus sakei ADM14 Improves Lipid Metabolism and Fecal Microbiota Profile Associated With Metabolic Dysfunction in a High-Fat Diet Mouse Model

Abstract

Effects of Latilactobacillus sakei ADM14 on changes in lipid metabolism and fecal microbiota composition were studied in high-fat diet (HFD) mouse model. The mice were divided into three groups: normal diet (ND), high-fat diet (HD), and HFD plus L. sakei ADM14 (HDA). Oral administration of L. sakei ADM14 daily for 10weeks decreased body weight gain, fat tissue mass, and liver weight in mice and reduced the size of histologically stained liver adipocytes. In addition, serum total cholesterol, triglycerides, and blood glucose decreased significantly. Latilactobacillus sakei ADM14 regulated the expression of genes related to lipid metabolism in epididymal adipose tissue and liver and induced changes in the composition of fecal microbiota, thereby improving energy harvests and changing metabolic disorder-related taxa. A significant decrease (p<0.05) in the Firmicutes to Bacteroidetes ratio was found in the HDA group compared to the HD group, particularly due to the difference in the relative abundance of the Bacteroidetes between the two groups over 10weeks. Differences in proportions of some taxa reported to have correlation with obesity were also found between HD and HDA groups. These results suggest that L. sakei ADM14 can have a positive effect on metabolic disorders such as obesity and fatty liver through effective regulation of host lipid metabolism and gut microbiota.

Latilactobacillus sakei QC9 alleviates hyperglycaemia in high-fat diet and streptozotocin-induced type 2 diabetes mellitus mice via the microbiota–gut–liver axis

“…Our results are consistent with previous studies, [56][57][58] several animal experiments and clinical studies have also shown that L. sakei can lower FBG, LDL-C, TC, and TG and play a good role in regulating the composition of the intestinal flora, thereby relieving lipid metabolism and weight loss. The liver also acts as one of the most important target organs for insulin, and the pancreas' primary duty is to release glucagon and insulin.…”

Physalis alkekengi L. Calyx Extract Alleviates Glycolipid Metabolic Disturbance and Inflammation by Modulating Gut Microbiota, Fecal Metabolites, and Glycolipid Metabolism Gene Expression in Obese Mice

“…Fatty acid synthase (FAS), acetyl-coA carboxylase 1 (ACC1), and stearoyl CoA desaturase (SCD) are the key enzymes in natural fatty acid synthesis [47]. A high-fat diet could significantly upregulate the transcription levels of FAS and ACC1 in the liver and increase the lipid synthesis load in the liver as well as significantly increase the levels of TG and LDL-C [31,48]. The current study showed that high-dose PC supplementation could significantly downregulate the expression levels of FAS, ACC1, and SCD1 in the liver.…”

Role of gut microbiota in the immunopathology of atherosclerosis: Focus on immune cells

“…Supplementation of Latilactobacillus sakei ADM14 in HFD mice shows a significant reduction in body weight, fat tissue mass, as well as total cholesterol, glucose and triglyceride levels 111 . Likewise, the mRNA levels related to fatty acid synthesis, such as sterol regulatory element‐binding protein‐1C, peroxisome proliferator‐activated receptor gamma and fatty acid synthetase, are downregulated by L. sakei ADM14, and the proportions of Bacteroides and Alistipes are increased, which are known as the main producers of SCFAs 111 . In addition, probiotics metabolize cholesterol to coprostanol, which is ultimately eliminated from the body via faeces, leading to the decrease in intestinal cholesterol absorption 110 .…”

“…111 Likewise, the mRNA levels related to fatty acid synthesis, such as sterol regulatory elementbinding protein-1C, peroxisome proliferator-activated receptor gamma and fatty acid synthetase, are downregulated by L. sakei ADM14, and the proportions of Bacteroides and Alistipes are increased, which are known as the main producers of SCFAs. 111 In addition, probiotics metabolize cholesterol to coprostanol, which is ultimately eliminated from the body via faeces, leading to the decrease in intestinal cholesterol absorption. 110 However, the mechanisms for the effects of probiotic bacteria on host lipid profiles remain poorly understood.…”

“…92,105,109,110 Shreds of evidence show that the efficacy of probiotics is associated with a reduction in total cholesterol and LDL-C. Supplementation of Latilactobacillus sakei ADM14 in HFD mice shows a significant reduction in body weight, fat tissue mass, as well as total cholesterol, glucose and triglyceride levels. 111 Likewise, the mRNA levels related to fatty acid synthesis, such as sterol regulatory elementbinding protein-1C, peroxisome proliferator-activated receptor gamma and fatty acid synthetase, are downregulated by L. sakei ADM14, and the proportions of Bacteroides and Alistipes are increased, which are known as the main producers of SCFAs. 111 In addition, probiotics metabolize cholesterol to coprostanol, which is ultimately eliminated from the body via faeces, leading to the decrease in intestinal cholesterol absorption.…”